Synopsis : Zydus Lifesciences reported strong YoY growth in Q2 with 38% EBITDA and 35% PAT jump, reaffirmed FY26 guidance with 26% EBITDA margin outlook, plans 25+ US launches this year, and board approved fundraise of up to Rs. 5,000 crore.

This pharma stock is one of India’s leading integrated pharma & biotech companies with strong presence across formulations, biologics, APIs, vaccines, wellness and complex generics is now in the focus after FY26 guidance targets 26% EBITDA.

With market capitalization of Rs. 95,089 cr, the shares of Zydus Lifesciences Ltd are closed at Rs. 944.10 per share, from its previous close of Rs. 936.70 per share.

QoQ view

Revenue declined from Rs. 6,574 Cr in Q1FY26 to Rs. 6,123 Cr in Q2FY26, downside of 7% EBITDA also declined 3.4% to Rs. 2,016 Cr fro

See Full Page